ADA 2025 presentations

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and asafety profile consistent with injectable GLP-1 medicines, incomplete Phase 3 results

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early…